Centessa Pharmaceuticals Appoints Gregory Weinhoff, M.D., MBA, as Chief Financial Officer and Expands Board of Directors
Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team. Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessa’s board of directors effective February 23, 2021.
“Centessa launched last month with a goal of redefining pharmaceutical R&D productivity through an asset-centric model that we believe has the potential to support the advancement of novel programs by industry-leading experts in their respective fields,” said Saurabh Saha, M.D., Ph.D., chief executive officer of Centessa. “Each member of our team brings industry-leading qualifications and differentiated perspectives to help guide the expansion of our organization. We are thrilled to welcome Greg, Mary Lynne, Robert and Samarth to Centessa and look forward to partnering together to build one of the most respected medicine companies in the world.”
“The enhanced scale and resources of Centessa, combined with the benefits of asset-centricity, can further accelerate development of important therapies,” said Dr. Weinhoff. “I am excited to work with the management team, board of directors, top healthcare investors and the industry leaders and subject matter experts at our Centessa subsidiaries to advance this bold new R&D model. We want to make Centessa a partner of choice for scientific entrepreneurs looking to accelerate the development of their discoveries and ultimately deliver impactful medicines for patients.”
Dr. Weinhoff joins Centessa after most recently co-founding and serving as chief financial and business officer of Arvelle Therapeutics B.V., which was acquired by Angelini Pharma in 2021 for $960 million. While with Arvelle, he raised a $207.8 million Series A financing and led the asset identification and in-licensing of cenobamate, a novel anti-seizure medicine with best-in-class efficacy. Previously, Dr. Weinhoff served as chief financial officer at Axovant Sciences, Inc., where he led financial functions and the execution of several private and public financings. Before Axovant, Dr. Weinhoff spent 15 years as an early-stage healthcare venture capitalist at CHL Medical Partners, where he was founding CEO of Amicus Therapeutics and his firm was the sole Series A investor. Dr. Weinhoff holds an M.D. from Harvard Medical School, an MBA from Harvard Business School and an A.B. in economics from Harvard College. Prior to graduate school, Dr. Weinhoff was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.
In addition to the company’s new chief financial officer, Centessa welcomes three new members to its board of directors:
- Mary Lynne Hedley, Ph.D., is a senior fellow and strategic advisor at the Broad Institute and former president, co-founder and chief operating officer at TESARO, Inc. She has extensive experience in the discovery and development of new medicines, formerly serving as executive vice president and chief scientific officer at MGI PHARMA, executive vice president of Eisai Corporation of North America, executive vice president of operations and chief scientific officer of Abraxis BioScience. Dr. Hedley holds a Ph.D. in immunology from the University of Texas Southwestern Medical Center and a B.S. in microbiology from Purdue University. In addition, she completed two consecutive postdoctoral fellowships at Harvard University.
- Robert M. Califf, M.D., MACC, is an internationally recognized expert in the development of medicines and in quality healthcare delivery with more than 40 years of clinical research and health outcomes expertise. He currently works as the head of strategy and clinical policy for Verily and Google Health. Dr. Califf served as the 22nd Commissioner of Food and Drugs for the U.S. Food and Drug Administration from 2016 to 2017 and has directed major initiatives targeted at improving methods and infrastructure for clinical research. As a graduate of the Duke University School of Medicine, he became the vice chancellor for health data science for the Duke University School of Medicine, is the founding director of the Duke Clinical Research Institute and remains a board certified cardiologist.
- Samarth Kulkarni, Ph.D., is the chief executive officer of CRISPR Therapeutics. Dr. Kulkarni brings expertise in strategy and operations in biotech with a wide range of cutting-edge therapeutic technologies. Prior to CRISPR, he was a partner at McKinsey & Company, where he had a leading role in the pharmaceutical and medical products practice. Dr. Kulkarni earned a Ph.D. in bioengineering and nanotechnology from the University of Washington and bachelor of technology from the Indian Institute of Technology.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals Limited is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams. Each program is developed by a Centessa subsidiary and supported by a centralized infrastructure and the Centessa management team. The company is headquartered in Cambridge, Mass. For more information, visit www.centessa.com.
This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts, which are usually identified by the use of words such as “estimates,” “expects,” “intends,” “anticipates,” “believes,” “may,” “should,” “will,” “plans,” “projects,” “seeks,” and variations of such words or similar expressions. These forward-looking statements, including statements relating to expectations, plans and prospects regarding the clinical development plans and timing, clinical trial designs, clinical and therapeutic potential, and strategy for any of our programs reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of clinical trials, regulatory filings, and approvals. These forward-looking statements are based upon the current expectations and beliefs of Centessa’s management team as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Furthermore, Centessa operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Dan Budwick, 1AB
UK/European media enquiries
Optimum Strategic Communications
Mary Clark, Shabnam Bashir
Swiss media enquiries
Cellphone: +41 79 20 75 111
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former Flex Executive Paul Humphries Joins Westfall Technik’s Board of Directors19.4.2021 03:19:00 CEST | Press release
Westfall Technik Inc. has added industry veteran Paul Humphries to its board of directors. Humphries worked with Westfall CEO Brian Jones and COO Mark Gomulka while at NASDAQ-listed Flex Ltd. (formerly Flextronics), and he has three decades of experience leading outsourced manufacturing services businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210418005057/en/ Paul Humphries, a former long-time, senior Flex executive, brings a wealth of experience to Westfall's board. He has spent years in the medical industry building global, high-reliability businesses. (Photo: Business Wire) Until his retirement in November 2020, Humphries spent two decades at Flex, the 160,000-employee, Singapore-based, multinational electronics contract manufacturer. In his most recent role at Flex, Humphries served as president for its High Reliability Solutions (HRS) unit, which generated $11 billion in annual revenue and served the medical,
NielsenIQ and J.D. Power Enter Strategic Alliance to Bring Unparalleled Automotive Research to Major Growth Markets19.4.2021 03:00:00 CEST | Press release
NielsenIQ, an industry leader in global measurement, and J.D. Power, a global leader in data analytics and consumer intelligence, today announced their intent to launch a multinational strategic alliance to bring benchmark automotive customer experience studies and deep auto industry data analysis to major growth markets such as India, Southeast Asia and the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210418005017/en/ Drawing on the strong market presence of NielsenIQ and the deep industry expertise of J.D. Power, the alliance will feature J.D. Power benchmark automotive studies, recognized as the gold standard in the automotive industry, complemented by NielsenIQ’s new digital and technology-based platforms and value-added services like social listening analysis. Combining NielsenIQ and J.D. Power capabilities will allow automotive sector clients to strategize for the future based on data-driven tools and in
Leading European Football Clubs Announce Participation in New Super League Competition19.4.2021 00:22:00 CEST | Press release
Twelve of Europe’s leading football clubs have today come together to announce they have agreed to establish a new mid-week competition, the Super League, governed by its Founding Clubs. AC Milan, Arsenal FC, Atlético de Madrid, Chelsea FC, FC Barcelona, FC Internazionale Milano, Juventus FC, Liverpool FC, Manchester City, Manchester United, Real Madrid CF and Tottenham Hotspur have all joined as Founding Clubs. It is anticipated that a further three clubs will join ahead of the inaugural season, which is intended to commence as soon as practicable. Going forward, the Founding Clubs look forward to holding discussions with UEFA and FIFA to work together in partnership to deliver the best outcomes for the new League and for football as a whole. The formation of the Super League comes at a time when the global pandemic has accelerated the instability in the existing European football economic model. Further, for a number of years, the Founding Clubs have had the objective of improving th
Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology16.4.2021 22:00:00 CEST | Press release
Bollé Safety, world leader in the design and manufacture of protective eyewear, presents its Healthcare division dedicated to all healthcare professionals. Its range of protective eyewear with anti-fog and anti-scratch PLATINUM® coating provides highly exposed employees with the highest levels of protection, clarity, and vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005009/en/ @BolléSafety - A.Childeric Viruses & infections’ protection Bollé Safety offers certified products compliant with the most stringent international standards. Its anti-fog PPE product range is tailored to protect professionals who are at high risk of being exposed to bodily fluids when providing care to patients. It is the company’s shared commitment to provide the highest quality protection for all healthcare workers. The importance of a clear vision Bollé Safety’s unique and exclusive permanent double sided anti-fog and anti-scratch PLA
Zeepay Ghana Acquires Mangwee Mobile Money in Zambia16.4.2021 19:55:00 CEST | Press release
Zeepay, the leading African Challenger Fintech with operations in over 10 African countries today acquired a 51 percent stake in Mangwee Mobile Money in Zambia. In a private placement Zeepay and Mangwee agreed to a sale of 51 percent of Mangwee shares to Zeepay. The deal makes Zeepay Ghana the majority shareholder of the entity. Mangwee has been in operations since 2018, and was initially set up to operate as an alternative wallet targeting university students in Zambia with the aim of assisting to drive the cost of mobile money services downward. Zeepay is the leading African challenger fintech with operations across 20 African countries and 30 day active in 10 of them. The company specializes in paying remittances into mobile money wallets across Africa and is regulated by both Bank of Ghana as an EMI issuer and in the UK as a Money Transfer Operator, by the Financial Conduct Authority. The merger is the first of its kind; that two Indigenous African fintechs into Mobile Money operat
CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future16.4.2021 18:29:00 CEST | Press release
Climate change is not taking a break from wreaking havoc in 2020, with the joint highest global temperatures on record, rampant bushfires, the faster rates of sea level rise and the extinction of some species. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005435/en/ Under this circumstance, Chinese President Xi Jinping, French President Emmanuel Macron, and German Chancellor Angela Merkel held a virtual meeting Friday on climate change, ahead of the Leaders' Climate Summit on Earth Day convened by the U.S., scheduled next week. Emphasizing that he always advocates building a community with a shared future for mankind, the Chinese president voiced his willingness to strengthen cooperation with France and Germany on climate change. "Tackling climate change is a common cause for all mankind and it should not become a geopolitical bargaining chip, a target for attacking other countries, or an excuse for trade barriers," h
Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 202116.4.2021 15:30:00 CEST | Press release
Colicity Inc. (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, completed on February 26, 2021 (the “Offering”) may elect to separately trade the Class A common stock and warrants included in the units commencing on or about April 16, 2021. Any Units not separated will continue to trade on The Nasdaq Capital Market under the symbol “COLIU,” and the Class A common stock and warrants will separately trade on The Nasdaq Capital Market under the symbols “COLI” and “COLIW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A common stock and warrants. This press release shall not constitute an o